Companies Report Positive Phase IIb Results for Neuropathic Pain Drug

GlaxoSmithKline and XenoPort, Inc. announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia in adults.
StreetInsider